Neutropenia is a common dose-limiting toxicity associated with irinotecan treatment. Although UGT1A1 variants have been associated with neutropenia, a fraction of neutropenia risk remains unaccounted for. To identify additional genetic markers contributing to variability in irinotecan pharmacokinetics and neutropenia, a regression analysis was performed in 78 irinotecantreated patients to analyze comprehensively three hepatic efflux transporter genes (ABCB1, ABCC1 and ABCG2). rs6498588 (ABCC1) and rs12720066 (ABCB1) were associated with increased SN-38 exposure, and rs17501331 (ABCC1) and rs12720066 were associated with lower absolute neutrophil count nadir. rs6498588 and a variant in high linkage disequilibrium are located in transcriptionally active regions or are predicted to alter transcription factor binding sites. While enhancer activity was not evident in vitro for genomic regions containing these single-nucleotide polymorphisms, rs6498588 was significantly associated with ABCC1 expression in human liver. These results suggest that genetic variation in ABCC1 and ABCB1 may contribute to irinotecan-induced neutropenia by altering expression of transporters involved in irinotecan metabolite disposition.
INTRODUCTION
Irinotecan is an antineoplastic prodrug approved for first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum and as a single agent for second-line therapy of fluorouracil refractory metastatic colorectal cancer. Common dose-limiting toxicities are diarrhea and neutropenia, 1 with up to 34% of patients experiencing grade 3-4 neutropenia. 2 Interindividual variation in irinotecan toxicity has prompted the search for genetic biomarkers to guide safer irinotecan treatment.
Irinotecan is activated to form the more potent topoisomerase I inhibiting active metabolite, SN-38.
3 Elevated SN-38 plasma concentrations have been associated with neutropenia during irinotecan treatment. [4] [5] [6] [7] SN-38 is subsequently inactivated to SN-38 glucuronide by members of the uridine diphosphate glucuronosyl transferase family, primarily UGT1A1 (ref. 8) (Figure 1 ). UGT1A1*28 has been associated with increased risk of neutropenia during irinotecan treatment. 5, [9] [10] [11] [12] The TA repeat polymorphism is located in the proximal promoter region of UGT1A1 and results in reduced expression relative to the UGT1A1*1 reference allele. Patients homozygous for UGT1A1*28 glucuronidate SN-38 less efficiently than patients who have one or more reference alleles; 10 subsequently, homozygous patients are especially susceptible to toxicities resulting from increased SN-38 systemic exposure (as measured by area under the plasma concentration-time curve (AUC)). UGT1A1*93 (rs10929302), a promoter polymorphism in high linkage disequilibrium (LD) with UGT1A1*28, has also been proposed as a predictor of neutropenia, with the variant being strongly associated with increased hematologic toxicity, 13 increased SN-38 exposure and lower absolute neutrophil count (ANC) nadir. [14] [15] [16] While UGT1A1*28-guided irinotecan dosing does reduce doselimiting toxicities, 17 variability in SN-38 AUC within genotypenormalized doses suggests that UGT1A1*28 does not account for all the toxicity observed during irinotecan therapy. Other studies have demonstrated more modest effects of UGT1A1 variants and propose that other metabolizing enzymes and drug transporters may be involved. [18] [19] [20] Irinotecan toxicity and increased SN-38 exposure have been previously associated with several hepatic transporter polymorphisms. 14, [21] [22] [23] The ATP-binding cassette (ABC) family includes proteins that transport irinotecan and its metabolites out of the cell. 24 ABCB1 variants have been associated with increased exposure to irinotecan and SN-38, 21 reduced irinotecan and SN-38 clearance 21, 25 and other toxic events. 15, 26 ABCC1 variants were previously associated with ANC nadir, SN-38 AUC and the ratio of SN-38 glucuronide AUC to SN-38 AUC, 14 and a common ABCG2 haplotype was also associated with neutropenia. 27 However, these associations have yet to be replicated and validated. Compared with UGT1A1, hepatic transporters are relatively unexplored, yet could have an important role in the distribution and accumulation of irinotecan and its metabolites.
In the current study, a genetic association analysis was performed to examine associations of ABCB1, ABCC1 and ABCG2 polymorphisms with irinotecan pharmacokinetics and neutropenia. An earlier pharmacogenetic analysis in this cohort included only a small number of polymorphisms in these three genes.
14 The present study covers the entire length and flanking regions of these genes for a more comprehensive analysis and tests the hypothesis that ABC transporter variants can contribute to additional variability in neutropenia observed during irinotecan treatment.
SUBJECTS AND METHODS Subjects
Human investigations were performed after review and approval by the Biological Sciences Division/University of Chicago Hospitals Institutional Review Board and in accordance with Federalwide Assurance for the protection of human subjects. Informed consent was obtained from all subjects. The study cohort consisted of 85 advanced cancer patients treated with single-agent irinotecan (300 mg m −2 or 350 mg m −2 ) every 3 weeks. Pharmacokinetic and clinical data, including race, sex, age, body surface area, SN-38 AUC, ANC nadir and baseline ANC, were collected. This patient population was examined in previous studies, 5, 14 and thus the sample size was not based on a priori calculation.
Genotyping
Tag single-nucleotide polymorphisms (SNP) were selected from genomic regions covering 25 kb upstream of the transcription start site to 5 kb downstream of the 3′-untranslated region (UTR) of each candidate gene (ABCB1, ABCC1 and ABCG2 
Statistical analysis
SNPs were tested for deviation from Hardy-Weinberg equilibrium using an exact test. Genotype-phenotype associations were analyzed using a twostage regression analysis in R v.3.2.2.
29 Dose-adjusted SN-38 AUC and ANC nadir values were log 10 -transformed for the analysis. In the univariate analysis, simple regressions were first performed on each variant and clinical covariate separately, and those with a significance level of P o0. 15 were kept for further analysis.
Step-wise backward selection of this subset of genotypes using the rms package 30 for R led to the final multivariable models, and model fit was assessed by examining R 2 values. An additive genetic model was first assumed for all genotype associations. To eliminate the driving effect of any sparse homozygous variants, when a particular variant had n ⩽ 3 observations in the homozygous genotype group and was significant, these genotypes were grouped with the heterozygous genotypes; the variant was kept in the model if still significant after combining genotypes.
Other statistical analyses were performed using GraphPad Prism v.6.0 (GraphPad Software, La Jolla, CA, USA). Comparisons for the risk alleles analysis and luciferase reporter assays were analyzed using a Figure 1 . Role of ATP-binding cassette (ABC) transporters and uridine diphosphate glucuronosyl transferase (UGT) enzymes in irinotecan pharmacokinetics and toxicity. The pathway is taken from PharmGKB (Stanford, CA, USA). Copyright PharmGKB. Permission has been given by PharmGKB and Stanford University. An original version is available online at https://www.pharmgkb.org/pathway/PA2001.
Mann-Whitney test or, if there were more than two groups, a KruskalWallis test, followed by Dunn's multiple comparisons test. Variance was assumed to be similar between compared groups, and two-sided P-values o0.05 were considered statistically significant.
Bioinformatic analysis
Significant SNPs and SNPs in high LD (r 2 ⩾ 0.8) were examined for evidence of changes in function and regulatory activity. HaploReg 31 and RegulomeDB 32 were used to determine whether the SNPs overlap with experimentally predicted functional elements (chromatin state segmentation, 33 DNase hypersensitivity peaks, chromatin immunoprecipitation-seq peaks) from the ENCODE Project 34 and the Roadmap Epigenomics Project. 35 HaploReg 31 and TRANSFAC Match 36 were used to identify and predict changes in transcription factor binding.
Measurement of enhancer activity in vitro
Primers were designed with the aid of Primer3 37, 38 to target 500 bp genomic regions flanking each significant SNP (Supplementary Table 2 ). These regions were PCR amplified using PfuTurbo (Agilent, Santa Clara, CA, USA) from human genomic DNA and cloned into the pGL4.23[luc2/minP] luciferase reporter vector (Promega, Madison, WI, USA). The QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent) was used to create the desired point mutation. Correct sequences were verified by Sanger sequencing. Reporter plasmids containing reference or variant sequences were transfected into Hep G2 (ATCC HB-8065, human hepatocellular carcinoma, passages 2-6) cells using Lipofectamine LTX and PLUS reagents (Invitrogen, Carlsbad, CA, USA). The Renilla luciferase construct pGL4.73 (Promega) was co-transfected to correct for transfection efficiency. Empty pGL4.23 vector and a known apolipoprotein E liver enhancer 39 were also transfected as negative and positive controls, respectively. Cells were cultured in Eagle's minimum essential medium with Earle's balanced salt solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, 1500 mg l −1 sodium bicarbonate and 10% fetal bovine serum. Twenty-four hours after transfection, luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega) and quantified using the GloMax-96 Microplate Luminometer (Promega). Backgroundsubtracted firefly luciferase activity was normalized with respect to Renilla luciferase activity and expressed as a mean value relative to empty pGL4.23 vector.
Code availability
The R code for the univariate and multivariate regression analyses is available at https://github.com/kroetzlab/irinotecan-ABC.
RESULTS

Cohort analysis
The original study cohort consisted of 85 patients, with the majority being Caucasian or African American. Seven subjects (2 Asian, 1 Filipino, 4 Hispanic) were omitted from the initial regression analyses to avoid dilution of association signals by genetic heterogeneity. Characteristics of patients included in the primary analysis are listed in Supplementary Table 3 . The analyzed cohort had a median age of 57 years and slightly more males (58%). The majority (76%) received a 350 mg m −2 dose of irinotecan, whereas 24% received a 300 mg m −2 dose. The outcomes examined in this study were SN-38 AUC (adjusted for irinotecan dose) and ANC nadir. Distributions of these phenotypes in the analyzed cohort are shown in Supplementary Figure 1 . Table 1) . The model explained 34% (R 2 = 0.345) of the variation in SN-38 exposure, with all three SNPs contributing similar variances to the model (rs12720066: β = − 0.337; rs6498588: β = 0.325; rs10929302: β = 0.390). The UGT1A1 and ABCC1 SNPs were associated with increased exposure of patients to SN-38, whereas the ABCB1 SNP was associated with decreased exposure (Figure 2) .
Inclusion of only Caucasian genotypes in the association analyses yielded similar results as obtained with the combined population (Supplementary Table 5 ). The multivariable model for log SN-38 AUC also contained UGT1A1*93, rs12720066 and rs6498588, with similar effect sizes as those for the model including African Americans. Inclusion of the seven Asian, Filipino and Hispanic subjects into the final model (Supplementary Table 6 ) resulted in similar coefficients and P-values.
Association of ABC SNPs with neutropenia
In univariate linear regression analyses of ABC SNPs with ANC nadir, 10 SNPs met the P o0.15 threshold and three (rs17501331, rs12720066 and rs3743527) had P-values o0.05 (Table 2) . Genotype frequencies of these SNPs are listed in Supplementary  Table 4 . The final model following multivariable regression and inclusion of UGT1A1*93 included an intronic SNP in ABCB1 (rs12720066) and an intronic SNP in ABCC1 (rs17501331) ( Table 2) . This model accounted for 39% (R 2 = 0.390) of the variation in ANC nadir, with UGT1A1*93 explaining more variance in the outcome (β = − 0.479) compared with the other two SNPs (rs17501331: β = − 0.295; rs12720066: β = 0.286). The ABCB1 SNP was associated with increased ANC nadir and the UGT1A1 and ABCC1 SNPs were associated with reduced nadirs (Figure 3) . As for the SN-38 AUC analysis, the final multivariable model for log ANC nadir for Caucasians only contained the same SNPs with similar effect sizes as those for the model including African Americans (Supplementary Table 7 ). Inclusion of the seven Asian, Filipino and Hispanic subjects into the final model (Supplementary Table 8 ) also resulted in similar coefficients and P-values. 
Contribution of multiple risk alleles
To examine the combined effects of risk alleles, composite genotypes were constructed for each outcome. Patients carrying more risk alleles for rs12720066, rs6498588 and UGT1A1*93 had significantly higher SN-38 AUC (P o 0.0001), whereas patients carrying more risk alleles for rs12720066, rs17501331 and UGT1A1*93 had significantly lower ANC values (P = 0.0006) (Supplementary Figure 2) . Almost all (91%) patients with grade 3-4 neutropenia ( o1000 cells per μl) carried at least four risk alleles among all three ABC SNPs and UGT1A1*93, compared with 53% of patients with no or less severe neutropenia (P = 0.001). Of the patients with grade 3-4 neutropenia, 91% are homozygous for rs12720066 and 46% are homozygous for UGT1A1*93, whereas of patients with no or less severe neutropenia, 73% are homozygous for rs12720066 and 7% are homozygous for UGT1A1*93. Doseadjusted SN-38 AUC was also confirmed to be higher in patients with grade 3-4 neutropenia (Supplementary Figure 3 ; P = 0.0001).
Bioinformatic analysis
To investigate the putative function of the SNPs in the final models, overlapping regulatory elements and protein binding sites were examined. The intronic ABCC1 SNP rs17501331 is in a predicted region of transcriptional transition in Hep G2 cells and is predicted to alter two regulatory motifs, DMRT1 and SOX6. rs6498588, located 11 kb upstream of ABCC1, is predicted to alter three regulatory motifs (GR, Mef2, YY1). rs4148330, a SNP in high LD (r 2 = 0.8) with rs6498588, resides 1.7 kb upstream of ABCC1 in a region with H3K4 methylation in Hep G2 cells and DNase hypersensitivity in Hep G2 cells and hepatocytes, and is predicted to alter E2F and NRSF transcription factor binding. rs12720066 and other SNPs in high LD with rs6498588 were also predicted to alter regulatory motifs but were not associated with an enrichment in enhancer or DNase activity in liver or liver-derived cells.
Enhancer assays Genomic regions containing the ABCB1 and ABCC1 SNPs in the final models for SN-38 AUC and ANC nadir plus additional SNPs in high LD with these variants (Supplementary Table 2 ) were tested in vitro for enhancer activity and the effect of genetic variation on this activity. None of the tested genomic regions exhibited significant enhancer activity and the introduction of the indicated variants did not change the transcriptional activity (Figure 4) .
DISCUSSION
This study provides a comprehensive analysis of the genetic variants spanning three hepatic ABC transporter genes of the irinotecan pharmacokinetic pathway. Three SNPs (rs12720066, rs6498588 and rs17501331) were significantly associated with changes in SN-38 AUC or ANC nadir. These variants could potentially predict neutropenia during irinotecan treatment and provide additional insight into the molecular mechanism of the toxicity.
UGT1A1*93 (rs10929302) was confirmed as a strong predictor of irinotecan-induced neutropenia, reflected by associations with higher SN-38 AUC and lower ANC nadirs. The effect sizes of UGT1A1*93 for associations with SN-38 AUC or ANC nadir were similar or slightly more significant compared with those of UGT1A1*28. UGT1A1*93 was previously associated with increased hematologic toxicity, increased SN-38 exposure and lower ANC nadir. [13] [14] [15] A recent study confirmed UGT1A1*93 as a more robust marker for neutropenia compared with UGT1A1*28.
16
The three ABC transporter SNPs in the final multivariable models are in noncoding regions, either intronic or upstream of their respective genes, and are not in high LD with any coding SNPs. This was expected, considering the low number of high-frequency coding SNPs in these genes. Previous studies of the effects of nonsynonymous SNPs on the expression and activity of these ABC transporters have yielded mostly negative or inconclusive results. [40] [41] [42] Of the SNPs with Po0.15 in the univariate analyses, only one (rs1128503) is in a coding region and one intronic SNP (rs2373586) is in high LD with a common missense SNP, rs2032582. rs1128503 and rs2032582 are both in ABCB1 and, together with rs1045642, make up the ABCB1*2 haplotype. This haplotype has been previously associated with early toxicity during irinotecan treatment. 26 However, these SNPs dropped out of significance during the selection of the multivariable models. These coding SNPs have been frequently studied together and individually for association with transporter activity and changes in exposure and response to numerous drugs, but with discordant results. 40 In contrast to coding SNPs, due to lower selective pressures and more modest effects, variants in the regulatory regions of membrane transporter genes are more abundant and exist at higher allele frequencies. 43, 44 Functional studies of variants in the proximal promoter, [44] [45] [46] [47] untranslated 48, 49 and intronic 50,51 regions of ABC and SLCO transporter genes have demonstrated changes in mRNA or protein expression levels and interindividual variation in pharmacokinetics. 52, 53 In light of this, it is likely that noncoding genetic variation has a more widespread impact on transporter function. Our results highlight the importance of including noncoding SNPs in pharmacogenetic studies and the need to further characterize regulatory regions in pharmacogenes.
The significant variants identified in this study may contribute to irinotecan-induced neutropenia by altering the expression of ABCB1 or ABCC1. ABCB1 encodes P-glycoprotein, which is involved in irinotecan and SN-38 biliary excretion. 54, 55 An increase in ABCB1 expression could result in increased biliary secretion of SN-38 and a corresponding reduction in plasma SN-38 levels, which are inversely correlated with ANC nadir. ABCC1 encodes MRP1, a hepatic basolateral efflux transporter of SN-38. 56 Increased ABCC1 expression is hypothesized to result in increased systemic levels of SN-38, which is consistent with the decreased ANC nadir associated with this variant. It should be noted that ABCC1/MRP1 expression in the liver is relatively low, 57 so increased expression ABCC1 and ABCB1 in irinotecan-induced neutropenia M Li et al may have a significant impact on basolateral efflux of SN-38 back into the blood. Bioinformatic analyses predicted 5′-flanking ABCC1 SNP rs6498588 to alter transcription factor binding and rs4148330 (in LD with rs6498588) to have both enhancer activity in hepatic cells and effects on transcription factor binding. A preliminary eQTL meta-analysis of human liver samples found rs6498588 to be significantly associated (meta-adjusted P = 0.05) with increased ABCC1 expression. 58 These data are consistent with the association of rs6498588 with increased SN-38 AUC, as higher ABCC1 expression would result in increased transport of SN-38 into the blood. However, our in vitro enhancer assays did not confirm these predictions for either rs6498588 or rs4148330. Enhancer assays conducted in additional hepatic cell lines or with different-sized genomic regions are warranted.
A combined allele analysis showed that a higher number of risk alleles from our models is correlated with irinotecan-induced toxicity. A significantly greater proportion of patients with grade 3-4 neutropenia carried at least four risk alleles for both phenotypes when compared with the group with no or less severe neutropenia. The risk alleles of rs12720066 and UGT1A1*93 appear to be driving this effect, with the directions of their effects consistent with the toxicity in both pharmacokinetic and pharmacodynamic outcomes. While rs6498588 was only in the final SN-38 AUC model, a SNP in high LD (rs8050881) had a weaker univariate association with ANC nadir; the variant alleles of these SNPs are also associated with the toxicity in both outcomes. However, the contribution of rs17501331 is less clear; this variant was only associated with ANC nadir and not at all with SN-38 AUC, suggesting a mechanism that may affect neutrophil count independent of SN-38 exposure. Given the complexity of the many metabolizing enzymes and transporters acting on SN-38, further eQTL and functional characterization studies are needed to validate the effect of these SNPs before proposing a combined PK/PD model.
The addition of rs6498588 to our previously published model 14 of log SN-38 AUC containing rs35605 (ABCC1), rs10276036 (ABCB1) and UGT1A1*93 improved the percent variation of SN-38 AUC explained by genetic determinants (adjusted R 2 increased from 0.221 to 0.284, P = 0.009, ANOVA), with all four variants in the model remaining significant. When rs12720066 and rs17501331 were added to our previous model of log ANC nadir 14 containing rs3765129 (ABCC1), rs2306283 (SLCO1B1) and UGT1A1*93, only rs17501331 had marginal significance (P = 0.05) and a smaller effect than the other variants in the initial model. The previously identified SNPs, especially UGT1A1*93, may explain more of the genetic variation in ANC nadir. Again, a better mechanistic understanding of this toxicity is needed before proposing a predictive multivariable model for irinotecan-induced neutropenia.
There are no known clinical associations of the variants identified in the current association studies. However, there is still enough compelling functional evidence to suggest that genetic variants in ABCB1 and ABCC1 are relevant to irinotecan toxicity. MRP1-overexpressing KB-3-1 cells showed increased SN-38 resistance compared with normal cells, 56 affirming that expression of the transporter does affect SN-38 transport. In ABCB1-knockout mice, irinotecan and SN-38 plasma levels were increased relative to the wild-type mice, consistent with a role for P-gp in biliary secretion of this drug/metabolite pair. 55 Cell lines overexpressing BCRP (encoded by ABCG2) are also resistant to irinotecan 59 and SN-38, 60 and ABCG2 421C4A reduced gene expression and conferred irinotecan resistance in cancer cell lines. 61 In the current study, there was no association with any of the tested ABCG2 variants and SN-38 exposure or ANC nadir.
Other genes in the irinotecan pharmacokinetic pathway including ABCC2, SLCO1B1, CES1, CES2 and CYP3A4, and additional variants in UGT1A1 and other UGT genes may also contribute to SN-38 exposure and neutropenia and warrant further study. [62] [63] [64] In contrast, genetic variation in genes responsible for irinotecan pharmacodynamics do not seem to have a role. 65 More comprehensive genotyping of pharmacokinetic genes has the potential to identify additional genetic variants more strongly associated with irinotecan exposure and toxicity. Discovery of additional genetic and non-genetic determinants of irinotecaninduced neutropenia will improve the predictive power of a clinical pharmacogenetic algorithm over using a single UGT1A1*28 test for drug selection and dosing. Replication and prospective studies in large independent cohorts as well as in other ethnic groups are necessary to validate and expand these findings.
A current gap in the field of pharmacogenetics is understanding the clinical value of variants. Our study used a pharmacokinetic/ pharmacodynamic phenotyping approach to discover new variants associated with neutropenia during irinotecan treatment. Further investigation of these variants and others in ABC transporter genes may not only potentially contribute to the improvement of individualized treatment with irinotecan but may also have broader implications for other substrates of ABC transporters.
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